A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Inclusion Criteria:

• Is at least 18 years of age and the local legal age of consent for clinical studieswhen signing the informed consent form (ICF).

• Has documented baseline mean platelet count of <30 x 10^9/L before randomization

• Has a documented duration of primary immune thrombocytopenia (ITP) of more than 12months on the date of informed consent form (ICF) signature.

• Has documented prior ITP treatment with at least 1 of the following treatments:corticosteroids, intravenous immunoglobulin (IVIg), anti-D immunoglobulin,thrombopoietin receptor agonist (TPO-RAs), or rituximab.

• Has documented insufficient response to a prior ITP treatment (the specific criteriacan be found in the protocol).

• Has documented prior response defined as 1 platelet count of ≥50 × 109/L to at least 1 of the following ITP treatments in the 3 years before the date of ICF signature:prednisone, dexamethasone, other or nonspecified corticosteroids, IVIg, or anti-Dimmunoglobulin

Exclusion Criteria:

• Other than the indication under study, known autoimmune disease or any medicalcondition that would interfere with an accurate assessment of clinical symptoms ofITP, confound the results of the study or put the participant at undue risk.

• Secondary ITP

• Nonimmune thrombocytopenia

• Autoimmune hemolytic anemia

• ITP-associated critical or severe bleeding The complete list of criteria can befound in the protocol.